TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00320203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 6 mg/mL
Description: Single injection, anterior juxtascleral depot (AJD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Single injection, anterior juxtascleral depot (AJD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: Single injection, anterior juxtascleral depot (AJD)
Study: NCT02338505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telelap ALF-X
Description: Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure.
Study: NCT00320203

Intervention type: OTHER
Group type: OTHER
Intervention: Anecortave Acetate Vehicle
Description: Single injection, anterior juxtascleral depot (AJD)
Study: NCT03593395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Mentoring [PM]
Description: Virtual Peer Mentoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Education Based Transition Program STE
Description: Education-based program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Education Based Transition Program STE
Description: Education-based program
Study: NCT03557112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
Study: NCT03288714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Transcranial Magnetic Stimulation (sTMS)
Description: sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
Study: NCT04622748

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: 8-min oral calculation and 5-min speech

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: 8-min oral calculation and 5-min speech
Study: NCT03158922

Intervention type: GENETIC
Intervention: Genetic SNP profiling
Description: Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

Intervention type: GENETIC
Intervention: Genetic SNP profiling
Description: Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

Intervention type: OTHER
Intervention: Prostate cancer screening
Description: Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.

Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
Study: NCT05869201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine [inactivated]
Description: Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
Study: NCT03996902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask-Advise-Refer
Description: The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
Study: NCT04495569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant anti-rabies human monoclonal antibody injection (SYN023)
Description: The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant anti-rabies human monoclonal antibody injection (SYN023)
Description: The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
Study: NCT01364376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
Description: FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium
Description: FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy
Study: NCT03311204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlephEx
Description: BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lid Hygenix
Description: Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
Study: NCT00599365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy care arm
Description: * The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~* You will need to give a complete list of medications to the pharmacist.~* You will need to describe how you take these medications.~* The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~* The pharmacist will give you a medication schedule, and other papers about your medications.
Study: NCT02700828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Study: NCT01345669

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily
Study: NCT01750723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 1 g diluted in 10 ml saline, i.v. bolus injection.
Study: NCT04478448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupirava
Description: 1 tablet contains 200 mg Favipiravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avigan
Description: 1 tablet contains 200 mg Favipiravir
Study: NCT00516165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
Study: NCT04078581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and fecal sample collection
Description: Questionnaire and fecal sample collection in order to select donors for FMT.
Study: NCT01665274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 resection
Description: D2 resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 resection
Description: D2 resection
Study: NCT00764621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primovist MRI
Description: Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
Study: NCT04168437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life Report
Description: Two page report and interpretation guide based on SPADE cluster scores
Study: NCT02813733

Intervention type: PROCEDURE
Intervention: Thyroid surgery
Description: Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
Study: NCT01288729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sure-T Steel Infusion Set Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sure-T Steel Infusion Set Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Study: NCT00781001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
Study: NCT01288729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick-Set Teflon Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick-Set Teflon Catheter
Description: Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
Study: NCT01263652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine
Description: IM/PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac hydroxyethylpyrrolidine
Description: IM/PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orphenadrine
Description: IM/PO orphenadrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orphenadrine
Description: IM/PO orphenadrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IM/PO tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IM/PO tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: PO/IM Dipyrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: PO/IM Dipyrone
Study: NCT01871870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Control Software
Description: This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
Study: NCT03550989

Intervention type: OTHER
Intervention: Non-Exposure Event
Description: Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.

Intervention type: OTHER
Intervention: Non-Exposure Event
Description: Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.

Intervention type: OTHER
Intervention: Non-Exposure Event
Description: Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.

Intervention type: OTHER
Intervention: Exposure Event
Description: Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).

Intervention type: OTHER
Intervention: Exposure Event
Description: Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).

Intervention type: OTHER
Intervention: Exposure Event
Description: Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).

Intervention type: OTHER
Intervention: Exposure Event
Description: Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
Study: NCT02862743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients with metastatic melanoma
Description: Blood sample to realize molecular characterization of melanoma
Study: NCT01772290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vismodegib
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Multiple oral doses
Study: NCT04492228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: \<30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: \<30g/day)
Study: NCT02589730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Welltang App
Description: This App is a large platform of individualized diabetic management

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Welltang App
Description: This App is a large platform of individualized diabetic management
Study: NCT00073346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Study: NCT02371434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)
Description: autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
Study: NCT02377297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with Fuji IX
Description: The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Vitro Molar
Description: The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Maxxion R
Description: The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
Study: NCT00580450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: 1.6 mg sc once a day for 16 weeks
Study: NCT00786214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients will be given sham acupuncture treatment at dummy acupuncture points
Study: NCT02404805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: dolutegravir tablets 50mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simeprevir
Description: simeprevir tablets 150mg, once daily x 7 days.
Study: NCT05973799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects remain fasted prior to insulin-induced hypoglycemia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding
Description: Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Study: NCT01175980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04623892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
Study: NCT00573261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Study: NCT04766645

Intervention type: DEVICE
Intervention: Robotic assisted intervention
Description: Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.

Intervention type: GENETIC
Intervention: epigenetic analyses
Description: Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical analyses
Description: Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
Study: NCT03304301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sunlight exposure
Description: Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months